Calciscon AG
Medical Devices - Biel/Bienne, Canton of Bern, Switzerland
Calciscon AG Employees
Calciscon AG Details
Calciscon develops and markets diagnostic devices for the assessment of calcification-related cardiovascular (CV) disease. CV disease is the leading cause of death worldwide, and vascular calcification is a most important driver of CV disease. Calciscon has developed and markets the T50 test, a novel and unique measurement of calcification. This medical information is critical to enable individualized care, and pivotal to reduce calcification and prevent cardiovascular disease. The T50 addresses a multi-billion market opportunity, and Calciscon will initially target patients with advanced chronic kidney disease (CKD), the patient group with the highest rate of calcification-related CV events (20x higher then normal population). The T50 test first enables the doctor to identify highest-risk patients, and then drives the selection of the most effective therapy to critically reduce calcification, to improve patient CV prognosis.
Calciscon AG Technologies
Email Providers
Outlook
Load Balancers
Apache
Tag Management
Google Tag Manager
Other
Microsoft Office 365
CSS and JavaScript Libraries
JQuery 1.11.1